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Abstract
The gene for a 45 kDa merozoite surface protein (MSA-2) of the human malaria parasite Plasmodium falciparum was PCR
amplified and cloned into eukaryotic expression vectors VR1012 and pcDNA3 to yield plasmids P1 and P2, respectively. The
coding sequences for two N-terminal fragments of the 185 kDa merozoite surface protein (MSA-1) gene were similarly PCR
amplified and cloned into vectors VR1020 and VR1012 to yield plasmids P3 and P4, respectively. The MSA-1 signal peptide
sequence, present in P4, was replaced with the human tissue plasminogen activator signal sequence in P3. The four plasmids
expressed the cloned genes under the control of the cytomegalovirus promoter and carried 3P bovine growth hormone
termination/poly A signals. P1, P3 and P4 also contained the cytomegalovirus intron A enhancer sequence. MSA-1
expression was more readily detected than MSA-2 in Cos cells transfected with P3/P4 and P1/P2 respectively. The MSA-2
gene was also cloned into the phagemid pBluescript IISK with and without a 3P poly A tail composed of 35 A residues.
MSA-2 was synthesised in HeLa cells infected with a recombinant vaccinia virus carrying T7 RNA polymerase when MSA-2
recombinant pBluescript was transfected into the cells. Inoculation with P1 intramuscularly or intradermally and with P2
intradermally into rabbits led to the production of antibodies to MSA-2 detectable by immunofluorescence and Western
blotting. Antibodies were also produced against MSA-1 after intramuscular/intradermal inoculation with P3 and P4.
Inoculation of rabbits with MSA-2 mRNA yielded better antibody titres when a poly A tail was present. Antibody levels
were maintained for s 9 weeks after the final immunisation. However the immune sera failed to inhibit in vitro parasite
growth. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The development of a malaria vaccine is hindered
by: (1) the presence of several parasite forms with
distinct target antigens that are susceptible to di¡er-
ent immune e¡ector mechanisms; (2) sophisticated
parasite strategies for immune evasion [1]; and (3)
the lack of e¡ective vaccine delivery systems and ad-
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Abbreviations: aa, amino acid; BGH, bovine growth hor-
mone; CMV, cytomegalovirus; DOTAP, N-[1-(2,3-D-dioleoyl-
oxy) propyl]-N,N,N-(trimethylammonium) methyl sulphate;
EGF, epidermal growth factor; ER, endoplasmic reticulum;
GPI, glycosylphosphatidyl inositol ; HBS, HEPES bu¡ered sa-
line; IFA, immuno£uorescence assay; mab, monoclonal anti-
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juvants. The demonstration that plasmids containing
foreign genes under the control of a mammalian cell
or virus promoter can directly transfect mammalian
cells has opened the possibility of DNA vaccination
[2]. DNA vaccination for malaria has many advan-
tages including: (1) the ease of production and stabil-
ity of a vaccine; (2) the ability to immunise against
many antigens using a mixture of plasmids; and (3)
the ability to e⁄ciently elicit cytotoxic and helper T-
cells and good antibody production. Gene transfer
through the introduction of mRNA is also possible,
leading to the concept of RNA vaccination [3].
Although mRNA is di⁄cult to prepare and less sta-
ble than plasmid DNA, it has the advantage that
chromosomal integration of the introduced nucleic
acid, which is a possible drawback with DNA vac-
cines, does not occur.
Because of their accessibility to antibodies, pro-
teins on the merozoite surface are candidate mole-
cules for developing a vaccine against asexual blood
stages of the malaria parasite. Monoclonal antibod-
ies (mabs) against a 45^50 kDa Plasmodium falcipa-
rum merozoite surface antigen, MSA-2 (alternatively
termed GYMSSA or PfMSP-2) [4,5], are reported to
inhibit parasite growth in vitro [6,7]. Some mabs
against a 185^200 kDa merozoite surface antigen
(termed MSA-1, PMMSA or PfMSP-1) similarly in-
hibit parasite growth [8], although other mabs can
prevent the inhibition [9]. Antibodies against MSA-
1 [10^12] and MSA-2 [13] in endemic area persons
have also been associated with protection against the
clinical symptoms of falciparum malaria.
MSA-2 occurs as two major allelic types that di¡er
chie£y in a central region composed of repetitive
sequences and the associated £anking regions. The
N-terminal 42 and C-terminal 75 amino acids are
largely conserved in di¡erent parasite isolates [14^
16]. Recombinant MSA-2 protein, derived from the
3D7 P. falciparum isolate and produced in Escheri-
chia coli has been recently used, together with a re-
combinant circumsporozoite protein, in a combined
Phase I and Phase II clinical trial. The proteins were
reported to be safe and immunogenic, but there was
no evidence of protective immunity against malaria
in the vaccinees [17]. We describe here the cloning
and expression of MSA-2 from the 3D7 P. falcipa-
rum isolate in mammalian cells and the antibody
response to MSA-2 based DNA and RNA vaccines
in rabbits.
Immunisation with intact MSA-1 or its C- and N-
terminal fragments protected Aotus and Saimiri mon-
keys against falciparum malaria [18^21]. Protection
in these animal models was related to high titre anti-
bodies. Antibodies to a C-terminal 19 kDa proteo-
lytically processed fragment of MSA-1, which is car-
ried into RBC by invading merozoites, are
particularly important for protective immunity [8].
However an 11 aa sequence located close to the N-
terminus of the mature protein is a constituent of
SPf66, a widely publicised malaria vaccine that re-
portedly protects against malaria [22]. Other reports
also suggest a role for the N-terminus of MSA-1 in
eliciting protection [11,12,19,20]. MSA-1 is essen-
tially coded for by dimorphic alleles capable of lim-
ited genetic exchange [23]. The MSA-1 sequence of
s 1700 aa has been divided into 17 blocks composed
of regions that are: (1) conserved; (2) semi-conserved
and; (3) variable between the two alleles. We cloned
two fragments of 1326 and 1386 bp, from the 5P end
of the MSA-1 gene, which di¡ered in the presence or
absence of the native signal peptide sequence, into
mammalian expression vectors for experimental
DNA immunisation of rabbits. The cloned region
of MSA-1 comprises blocks 1^5 plus a portion of
block 6 [23]. Blocks 1, 3 and 5 are conserved regions
while blocks 2 and 4 are di¡erent in the two alleles
[23]. Block 2 is composed of the repeated sequence
SGASAQ in the 3D7 isolate that ¢ts the consensus
repeat sequence SXXSXX for block 2.
Immunisation with synthetic peptides containing
known B-cell epitopes from MSA-1 and MSA-2
coupled to diphtheria toxoid as a carrier molecule
in a Phase I clinical trial, showed good antibody
formation [24]. However, an unacceptable level of
C
Fig. 1. (A) Map of plasmid P1 derived by cloning the MSA-2 coding sequence into VR1012. (B) Map of plasmid P2 derived by clon-
ing the MSA-2 coding sequence into pcDNA3 (Invitrogen, USA). (C) Map of plasmid BKG which was produced by cloning the
MSA-2 coding sequence into pBluescript SKII. (D) Map of plasmid P3 derived by cloning a 1326 bp MSA-1 sequence into VR1020.
(E) Map of plasmid P4 derived by cloning a 1386 bp MSA-1 sequence, including the signal peptide sequence, into VR1012.
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type III (Arthus) hypersensitivity to the toxoid was
observed in the immunised individuals [24] and this
precluded a subsequent Phase II trial. Experimental
nucleic acid immunisation with the two merozoite
proteins was expected to overcome some of the dis-
advantages of the peptide^diphtheria toxoid system.
2. Materials and methods
2.1. Cloning of MSA-2 gene fragments into
mammalian expression vectors
DNA isolated from 3D7 parasites by binding to
Sephaglas (Pharmacia) [14], was used as a template
for PCR amplifying the 819 bp coding sequence of
the MSA-2 gene. The forward and reverse primers
employed were AAAGTCGACATGAAGGTAAT-
TAAAAC (designed to yield a SalI site) and
ACAAAGCTTGGATCCTTATATGAATATGG-
CAAAAGATA (designed to yield a BamHI site),
respectively. The ampli¢ed gene was cloned into the
SalI^BamHI site of the eukaryotic expression vector
VR1012 [25,26] to yield plasmid P1 (Fig. 1A). Ex-
pression in P1 is under the control of a human cy-
tomegalovirus (CMV) immediate-early gene pro-
moter and a CMV intron A enhancer. P1 also
carries a bovine growth hormone (BGH) termina-
tion/poly A signal 3P to the cloned gene fragment.
Vector VR1012 (and VR1020 described below)
kindly provided by Drs. R.C. Hedstrom and S.L.
Ho¡man of the Naval Medical Research Institute,
MD, USA, had the ampicillin resistance gene found
in pUC18-derived plasmids replaced by a kanamycin
resistance gene. The PCR ampli¢ed MSA-2 gene was
also cloned into the SalI^BamHI site of the phage-
mid pBluescript IISK (Stratagene, USA). pBlue-
script II carries T7 and T3 RNA polymerase pro-
moter sequences £anking the multiple cloning site.
The sequence of the cloned gene was con¢rmed by
dideoxynucleotide sequencing [27]. The MSA-2 gene
was excised from pBluescript IISK as a KpnI^BamH
I fragment and cloned into the KpnI^BamHI site of
the eukaryotic expression vector pcDNA3 (Invitro-
gen, USA) to yield plasmid P2 (Fig. 1B). Expression
of the cloned gene in P2 is under the control of a
CMV promoter and BGH termination/polyadenyla-
tion signals.
2.2. Production of MSA-2 mRNA
pBluescript SKII carrying MSA-2 (Fig. 1C) was
cleaved with BamHI and NotI within the polylinker
site of the phagemid, and a double-stranded deoxy-
oligonucleotide containing the coding strand se-
quence (A)35 £anked by BamHI and NotI sites
cloned into the 3P end of the MSA-2 gene. The se-
quence of the two oligonucleotides used were GAT-
CC(A)35GC for the coding strand and GGCCG-
C(T)35G for the template strand. Clones of phag-
emid containing the poly A tail were selected by
the presence of a 230 bp NotI^XbaI fragment. The
phagemids carrying the MSA-2 gene with and with-
out the poly A tail were termed BKA and BKG,
respectively. Approximately 40 Wg mRNA were tran-
scribed, using the T7 Cap-Scribe reagents (Boeh-
ringer, Germany) from 0.5 Wg of each of the two
phagemids linearised by NotI digestion, and then pu-
ri¢ed by ethanol precipitation according to the man-
ufacturer’s instructions. The products incorporated
m7G(5P)ppp(5P)G caps for stability and e⁄cient
translation. On analysis in denaturing agarose
gels [27], the RNA transcribed from BKG mi-
grated as expected of a 839 nucleotide species,
while BKA RNA migrated as a slightly larger
molecule corresponding to an expected size of 862
nucleotides.
2.3. Cloning of MSA-1 gene fragments into
mammalian expression vectors
A 1386 bp fragment of MSA-1 DNA coding for a
462 aa N-terminal polypeptide including the initiat-
ing methionine was PCR ampli¢ed using the forward
primer RR96-5 and the reverse primer RR96-20. A
1326 bp DNA fragment coding for a 442 aa N-ter-
minal polypeptide, where 20 aa corresponding to the
signal peptide and an additional valine were absent,
was similarly PCR ampli¢ed with RR96-21 as the
forward primer and RR96-20 as the reverse primer.
RR96-5 incorporates a site for SalI, while RR96-20
and RR96-21 incorporate sites for BamHI. The se-
quences of the primers were: RR96-5, AAAGTC-
GACATGAAGATCATATTCTTTTTATGTTCAT-
TTC; RR96-20, TAATGGATCCTTCGTGTTCCT-
CGATTTT; and RR96-21, CCCGGATCCACACA-
TGAAAGTTATCAAG.
BBADIS 61760 23-12-98
R. Ramasamy et al. / Biochimica et Biophysica Acta 1453 (1999) 1^134
The gene fragment coding for the MSA-1 protein
without the signal peptide was cloned into the Bam-
HI site of the eukaryotic expression vector VR1020
to yield plasmid P3 (Fig. 1D). A human tissue plas-
minogen activator (tPA) signal peptide sequence is
incorporated 5P to the cloned gene in P3. The
MSA-1 gene fragment bearing the sequence for the
native signal peptide was cloned into VR1012 as a
SalI^BamHI fragment to yield plasmid P4 (Fig. 1E).
VR1012 di¡ered from VR1020 chie£y in lacking the
tPA signal sequence. P4 clones were selected from
minipreps [27] by the presence of the appropriate
size SalI^BamHI fragment. The selection of recombi-
nant VR1020 colonies was aided by a digoxigenin-
tagged MSA-1 probe prepared by random primed
labelling of the PCR ampli¢ed MSA-1 DNA with
digoxigenin labelled dUTP according to the manu-
facturer’s instructions (DIG labelling kit, Boehringer,
Germany) and alkaline phosphatase conjugated anti-
digoxigenin antibodies [28]. P3 clones containing the
inserted DNA fragment in the correct orientation
were subsequently selected from recombinant
VR1020 clones by the detection of the appropriate
size HindIII digestion fragments from miniprep
DNA.
2.4. Preparation of plasmid DNA for immunisation
Clones grown in DH5K cells were used to isolate
plasmid DNA on Qiagen columns according to the
manufacturer’s instructions (Qiagen, Germany).
Plasmid DNA was dissolved in water, the concentra-
tion and purity determined by measuring absorbance
at 260 and 280 nm, and stored in aliquots at approx-
imately 1 mg ml31 at 320‡C.
2.5. Antibodies to MSA-1 and MSA-2
The IgG1 mouse mab 12.2 reacting with the allele-
speci¢c block 2 repeats found at the N-terminus of
3D7 MSA-1 and IgG1 mabs 12.3 and 12.7 reacting
with the allele-speci¢c region of 3D7 MSA-2 were
kindly provided as ascites £uids by Dr. J. McBride
of the University of Edinburgh. Rabbit antiserum to
MSA-2 was also raised by immunisation with a pu-
ri¢ed MSA-2^glutathione S-transferase fusion pro-
tein.
2.6. Expression of MSA-1 and MSA-2 in Cos-1 cells
Cos-1 SV40 transformed monkey cells (ATCC
CRL-1650) grown in RPMI 1640 (Sigma) containing
10% foetal calf serum, were transfected with 2^8 Wg
plasmid DNA using the N-[1-(2,3-D dioleoyloxy)
propyl]-N,N,N-(trimethylammonium) methyl sul-
phate (DOTAP) transfection reagent (Boehringer,
Germany) according to the manufacturer’s instruc-
tions. Approximately 12% of cells were transfected
by this procedure when the transfection e⁄ciency
was determined by using an eukaryotic expression
vector carrying L-galactosidase (pCH110, Pharma-
cia) and staining with X-gal (R. Ramasamy, unpub-
lished data). After 48 h of culture, the transformed
Cos cells were washed and lysed by adding Laemmli
sample bu¡er [29]. After boiling at 100‡C, the lysate
was repeatedly passed through a 27-gauge needle to
shear DNA and aliquots were used for SDS-PAGE
[29], transferred to nitrocellulose [30] and probed
with speci¢c mabs in Western blots. Cos cells simi-
larly transfected in parallel with non-recombinant
expression vectors were used as a control.
2.7. Expression of MSA-2 in the vaccinia/T7 transient
expression system [31]
HeLa cells grown to 80% con£uence in 25 cm2
tissue culture £asks were washed in 0.01 M phos-
phate bu¡ered saline, pH 7.2 (PBS) and infected
with a recombinant vaccinia virus strain (vTF7-3)
carrying the T7 RNA polymerase gene at 30 pfu
per cell for 30 min at 37‡C. The infected cells were
then transfected with 4 or 20 Wg BKG DNA mixed
with 27 Wg DOTAP. After 24 h, the HeLa cells were
collected, washed and then lysed in Laemmli sample
bu¡er and used for Western blots as described above.
2.8. DNA immunisation of rabbits against MSA-2
with plasmids P1 and P2
P1 and P2 were each used separately to intrader-
mally immunise two New Zealand white rabbits. Ad-
ditionally, P1 was used to intramuscularly immunise
two other rabbits. Each rabbit was immunised four
times at 3 week intervals. The rabbits were ear bled
before immunisation to yield the prebleed serum and
then 3 weeks after each immunisation. For each rab-
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bit immunisation, 25 Wg DNA was mixed with DO-
TAP liposomes according to the manufacturer’s in-
structions (Boehringer, Germany). Immunisation was
carried out intradermally at multiple sites using
washed and sterilised commercial tuberculin applica-
tors. Intramuscular injections were performed at two
sites per rabbit using a sterile 1 ml disposable sy-
ringe. Rabbits were immunised with non-recombi-
nant plasmids VR1012 and pcDNA3 in parallel as
controls. Rabbits T1 and T2, immunised intramuscu-
larly with P1, were additionally bled 11 weeks after
the fourth immunisation and rabbit T5, immunised
intradermally with P1, was bled 14 weeks after the
fourth immunisation to test for persistence of anti-
bodies. The care and use of animals were according
to WHO guidelines (WHO88.1).
2.9. RNA immunisation of rabbits against MSA-2
with BKA and BKG
Forty Wg of BKA mRNA was mixed with 125 Wg
DOTAP in a volume of 300 Wl sterile HBS as de-
scribed above and 230 Wl injected intramuscularly
into a rabbit at two sites. The remaining 70 Wl of
the mRNA/DOTAP mix was inoculated intrader-
mally at multiple sites using a tuberculin applicator.
Another rabbit was injected with BKG mRNA in an
identical manner. Three immunisations were per-
formed at 3 week intervals. The rabbits were ear
bled before immunisation to yield the prebleed serum
and then 14 days after each immunisation. A ¢nal
bleed was obtained 15 weeks after the third immuni-
sation to test the persistence of antibodies in the
rabbit injected with BKA mRNA.
2.10. DNA immunisation of rabbits against MSA-1
with plasmids P3 and P4
Each plasmid was injected into two New Zealand
white rabbits at 3 week intervals. The rabbits were
ear bled before immunisation to yield preimmune
serum and then 3 weeks after each immunisation.
For each rabbit immunisation, 25 Wg DNA was com-
plexed with DOTAP. Due to the limited availability
of DOTAP and other reagents, only one protocol for
immunisation with the two plasmids was possible.
The ¢rst three immunisations were done by intra-
muscular injection at two sites per rabbit. The fourth
immunisation was performed intradermally at multi-
ple sites using a washed and sterile commercial tuber-
culin applicator with half the DOTAP^DNA com-
plexes (12.5 Wg DNA). The remainder was injected
intramuscularly into the same rabbit. Sera were also
obtained 9 and 48 weeks after the fourth immunisa-
tion from the two more strongly responding rabbits
injected with each construct (rabbits 2 and 4) to test
for the persistence of antibodies.
2.11. Immuno£uorescence assay (IFA) and Western
blots on parasite lysate
IFA and Western blots were performed on late
stage 3D7 parasites, prepared by gelatine sedimenta-
tion, as described previously [4]. Antibody titres were
determined using serial 10-fold dilutions of sera or
IgG preparations.
2.12. Enzyme-linked immunosorbent assay (ELISA)
on MSA-1 and MSA-2 peptides
Peptide P109 VTHESYQELVKKLEALEDAC
containing the N-terminal sequence of the mature
MSA-1 protein with an added C-terminal cysteine,
was used to assay antibodies to MSA-1 as previously
described [32]. Two peptides derived from the con-
served N- and C-terminal regions of the MSA-2 mol-
ecule were used similarly in the ELISA for MSA-2
antibodies. The peptides were P101 (NESKYSNT-
FINNAYNMSIRC, residues 23^40 of the FC27 iso-
late sequence with an additional C-terminal cysteine)
and P103 (RNNHPQNTSDSQKEATDGNKC, resi-
dues 207^226 of the FC27 isolate sequence with an
alanine replacing a cysteine at position 221 of the
native sequence and a C-terminal cysteine introduced
for coupling purposes).
2.13. Parasite growth inhibition assay
The 3D7 isolate of P. falciparum from Dr. D.
Walliker, University of Edinburgh was used for
measuring rabbit IgG antibody-mediated growth in-
hibition by microscopy and [3H]hypoxanthine incor-
poration [33,34]. IgG was prepared from rabbit sera
preabsorbed with human RBCs, by precipitation
with 50% ammonium sulphate and exhaustive dialy-
sis into RPMI 1640. The IgG content as estimated by
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SDS-PAGE analysis [29] was 50%. Protein concen-
tration was determined by a Lowry assay [35]. In
other growth invasion experiments, rabbit sera pre-
absorbed with human RBCs were used at 10% v/v to
replace human serum in the culture medium. Preim-
mune rabbit IgG and sera were used as controls.
3. Results
3.1. Expression of MSA-2 in Cos and HeLa cells
Transfection of Cos cells with P1 and P2 showed
that the MSA-2 was only weakly detected in Western
blots probed with the MSA-2 speci¢c antibodies.
Synthesis of MSA-2 in the vaccinia/T7 polymerase
transient expression system, which is reportedly two
orders of magnitude more e⁄cient than the conven-
tional system [31], was therefore attempted. HeLa
cells infected with recombinant vaccinia virus ex-
pressing T7 RNA polymerase and then transfected
with 4 Wg BKG in 27 Wg DOTAP, synthesised
MSA-2 that was readily detected in Western blots
(Fig. 2). The use of a higher DNA to DOTAP ratio
in the transfection assay reduced the e⁄ciency of
transfection/expression. The MSA-2 synthesised in
HeLa cells migrated as a 50 kDa protein on SDS-
PAGE. The observed size of the MSA-2 synthesised
in HeLa cells is similar to the apparent Mr of re-
combinant MSA-2 produced in Escherichia coli
(Fig. 2) and parasite synthesised MSA-2 (Figs. 3^
5). The observed Mr is almost double the molecular
mass of 27 972 predicted for the 273 residue protein.
3.2. Antibody response to DNA and RNA
immunisation with MSA-2
Intramuscular injection of P1 DNA into rabbits
led to the production of antibodies to MSA-2 detect-
able by Western blotting (Fig. 3). Antibodies were
also produced in rabbits after intradermal inocula-
tion of P1 DNA (Fig. 4) and P2 DNA (Fig. 5). Para-
site synthesised MSA-2 was detected as a broad and
sometimes split band in Western blots (e.g. Fig. 3,
Fig. 2. Western blot showing the synthesis of MSA-2 in HeLa
cells transfected with pBluescript SKII carrying the MSA-2
gene (BKG) after infection of the cells with recombinant vacci-
nia coding for T7 RNA polymerase. One million vaccinia in-
fected HeLa cells were transfected with: lane a, 4 Wg control
pBluescript SKII; lane b, 4 Wg BKG; lane c, 20 Wg BKG and
10% of the lysates separated on 10% gels. Lane d, 100 ng re-
combinant MSA-2 protein produced in E. coli. Mab 12.3 was
used as the ¢rst antibody for probing the blot. The migration
positions of marker proteins are indicated in kDa and of MSA-
2 by an arrow. df, dye front. The prominent 90, 30 and 23
kDa bands in lanes a^c probably represent HeLa cell or vacci-
nia proteins recognised by antibodies in the ascites £uid con-
taining mab 12.3.
Fig. 3. Antibody production after intramuscular injection of
rabbit T2 with P1 DNA. Western blots of 3D7 parasite lysates
were probed with 1032 dilution of serum obtained 3 weeks
after: lane a, one injection; lane b, two injections; lane c, three
injections; and lane d, four 4 injections. Lane e, parasites
probed with 1033 dilution of the serum obtained 3 weeks after
the four the injection; lane f, parasites probed with 1032 dilu-
tion of serum obtained 11 weeks after the fourth injection; lane
g, parasites probed with 1:500 dilution of antiserum to re-
combinant MSA-2 protein. Migration positions of marker pro-
teins are indicated in kDa and of MSA-2 by an asterisk.
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lane d and Fig. 4, lane h). Antibodies were also
clearly detected by immuno£uorescence and weakly
by Western blotting after immmunisation of rabbits
with BKA mRNA. The reaction of sera from BKG
mRNA inoculated rabbit with parasites was only
detectable weakly by IFA at 1031 dilution.
None of the sera from the DNA or RNA immu-
nised rabbits, when tested at dilutions of 1031 to
1034, reacted with the two peptides from the con-
served N- and C-termini of MSA-2 in an ELISA.
Antibodies were detectable by IFA after three immu-
nisations in all rabbits subject to DNA and RNA
vaccination with MSA-2. The IFA pattern observed
on late stage schizonts resembled a bunch of grapes
which is characteristic of reaction with antigens, such
as MSA-2, present on the merozoite surface [4]. No
IFA or Western blot reactions were seen with the
sera of control rabbits immunised with non-recombi-
nant plasmids or preimmune sera from the rabbits
immunised with P1, P2 or BKA. The results of anti-
body assays performed on the immune rabbit sera
are summarised in Table 1.
Fig. 4. Antibody production after intradermal inoculation of
rabbit T5 with P1 DNA. Western blots of 3D7 parasite lysates
were probed with 1032 dilution of serum obtained: lane a, be-
fore immunisation; lane b, 3 weeks after one inoculation; lane
c, 3 weeks after two inoculations; lane d, 3 weeks after three
inoculations; lane e, 3 weeks after four inoculations. Lane f,
parasites probed with 1033 dilution of the serum obtained
3 weeks after four inoculations; lane g, parasites probed with
1032 dilution of serum obtained 14 weeks after the fourth inoc-
ulation; lane h, parasites probed with 1033 dilution of antise-
rum to recombinant MSA-2 protein. Migration positions of
marker proteins are indicated in kDa and of MSA-2 by an as-
terisk.
Table 1
Antibody response to MSA-2 after DNA and RNA immunisation
Immunogen
(route of inoculation)
Rabbit IFA titre after
3rd immunisation
Western blot
titre after
4th immunisation
Characteristics of Western blots
P1 (intramuscular) T1 1032 1032 Ab ¢rst detected after 3 immunisations and at 1032
dilution 11 weeks after 4th immunisation
P1 (intramuscular) T2 1032 1033 Ab ¢rst detected after 3 immunisations and at 1032
dilution 11 weeks after 4th immunisation
P1 (intradermal) T5 1032 1033 Ab ¢rst detected after 2 immunisations and at 1032
dilution 14 weeks after 4th immunisation
P1 (intradermal) T6 1032 1033 Ab ¢rst detected after 2 immunisations
P2 (intradermal) T7 1032 1032 Ab ¢rst detected after 3 immunisations
P2 (intradermal) T8 1032 1032 Ab ¢rst detected after 3 immunisations
BKA mRNA BKA 1032 (also detected at
15 weeks after
3rd immunisation at
1032 dilution)
1032 (after
3rd immunisation)
Ab ¢rst detected after 3 immunisations. Weak
reaction. Only 3 immunisations performed
BKG mRNA BKG 1031 (weak) negative (after
3rd immunisation)
Only 3 immunisations performed
BBADIS 61760 23-12-98
R. Ramasamy et al. / Biochimica et Biophysica Acta 1453 (1999) 1^138
None of the sera from immunised rabbits used at
10% v/v in cultures, or IgG from immunised rabbits
T1, T7 and BKA at concentrations in the range 2 Wg
ml31 to 2 mg ml31 in cultures, signi¢cantly inhibited
parasite growth compared to preimmune sera or IgG
from the same rabbits in a [3H]hypoxanthine incor-
poration assay. In one experiment, for example, at 2
mg ml31 T1 IgG obtained after four injections gave
14566 þ 1028 (cpm þ S.E.) while preimmune T1 IgG
gave 15520 þ 1429 (cpm þ S.E.) at the same concen-
tration incorporation into parasites.
3.3. Expression of MSA-1 in Cos cells
Cos-1 cells transfected with P3 and P4 synthesised
a protein of the expected Mr of approximately 50
kDa that reacted with the anti MSA-1 mab 12.2. in
Western blots (asterisk in Fig. 6). Smaller proteins
reacting with the mab in P3 and P4 transfected cells
are probably degradation products (Fig. 6).
3.4. Antibody response to DNA immunisation with
MSA-1
The results of antibody assays performed with im-
mune sera obtained after four immunisations with P3
and P4 are summarised in Table 2. Sera obtained
Fig. 6. Western blot of: lane a, late stages of P. falciparum
3D7 isolate, and Cos cells transfected with lane b, 4 Wg of con-
trol plasmid pcDNA3; lane c, 4 Wg plasmid P4; lane d, 8 Wg
P4; lane e, 4 Wg P3; and lane f, 8 Wg P3. The blot was probed
with mab 12.2 against MSA-1. The migration position of intact
MSA-1 and its major fragments recognised by mab 12.2 in the
parasite lysate (lane a) are indicated by arrows. The migration
position of the MSA-1 fragment synthesised in Cos cells is indi-
cated by an asterisk. The migration positions of the di¡erent
molecular weight markers are also shown.
Table 2
Antibody response to MSA-1 after DNA immunisation
Rabbit
(immunogen)
ELISA titre on P109 after
four immunisations
IFA titre after four immunisations
No. 1 (P3) negative 1031
No. 2 (P3) 1032 1032 (Ab ¢rst detected at 1031 dilution after 2nd immunisation.
Maintained for 9 weeks after 4th immunisation)
No. 3 (P4) negative 1031
No. 4 (P4) 1032 1033 (Ab ¢rst detected at 1031 dilution after 2nd immunisation.
Maintained for 9 weeks after 4th immunisation)
Fig. 5. Antibody production in rabbit T7 after intradermal in-
oculation with P2 DNA. Western blots of 3D7 parasite lysates
were probed with: lane a, antiserum to recombinant MSA-2
protein at 1:500 dilution; and lane b, T7 serum at 1032 dilu-
tion obtained 3 weeks after the third inoculation. Migration po-
sitions of marker proteins are indicated in kDa and of MSA-2
by an asterisk.
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from one rabbit of each category after four immuni-
sations, showed a detectable antibody response to
MSA-1 by ELISA with peptide P109. Sera from all
the rabbits after four immunisations gave a clear
IFA £uorescence pattern on late schizonts resem-
bling a bunch of grapes that is indicative of reaction
with the merozoite surface [4]. However, the same
sera only reacted weakly with MSA-1 in Western
blots (data not shown). IFA antibody titres, which
were maintained for at least 9 weeks after the fourth
immunisation in the two more strongly responding
rabbits (nos. 2 and 4), declined to background levels
by 48 weeks. Sera from rabbits immunised with con-
trol plasmids or the preimmune sera from the immu-
nised rabbits did not react with MSA-1 in any of the
antibody assays.
Immune rabbit sera at 10% v/v or IgG prepara-
tions at concentrations in the range of 1 Wg ml31 to
1 mg ml31 did not inhibit P. falciparum growth over
48 h as determined by either microscopy or the
[3H]hypoxanthine incorporation assay. For example,
in one experiment, rabbit no. 4 preimmune IgG at
1 mg ml31 yielded 11690 þ 816 (cpm þ S.D.) while
IgG from the same rabbit after four immunisations
at 1 mg ml31 yielded 13988 þ 2561 (cpm þ S.D.) in
the [3H]hypoxanthine incorporation assay.
4. Discussion
Transient transfection assays were ¢rst used to
demonstrate that the cloned merozoite proteins are
synthesised in primate cells. The 462 aa N-terminal
MSA-1 fragment was better expressed than the 273
aa MSA-2 protein when the corresponding genes
were cloned into VR1012 and transfected into Cos
cells. The explanation for this is not clear, but may
be related to characteristics of the two gene or pro-
tein fragments. For example, the MSA-2 molecule
carries native signals for translocation into the endo-
plasmic reticulum (ER) and the addition of a mem-
brane anchoring glycosylphosphatidyl inositol (GPI)
moiety, while the MSA-1 fragment only carries the
ER signal. The results also show that MSA-1 poly-
peptide carrying the human tPA signal peptide (in
VR1020) or the native signal peptide (in VR1012)
was about equally expressed in Cos cells. Although
the general structural features of signal peptides are
conserved from bacteria to man, few malaria parasite
genes coding for exported or membrane proteins
have previously been tested for protein expression
in primate cells. More detailed studies, including de-
termining the de¢nitive subcellular location of MSA-
1 and 2 synthesised in primate cells, are necessary for
establishing whether parasite signal sequences for ER
export or the addition of a GPI moiety are recog-
nised in these cells.
The anomalous migration of MSA-2 in SDS-
PAGE is not due to glycosylation or the attachment
of the GPI moiety since recombinant MSA-2 pro-
duced in E. coli also migrated as a 50 kDa protein
on SDS-PAGE. The presence of repeats and £anking
sequences with unusual amino acid composition [1]
and the acidic nature of MSA-2 (predicted pI 5.25)
may be responsible for the retarded migration of
MSA-2 in SDS-PAGE. A recombinant protein con-
taining the proline rich repetitive region of the P.
berghei thrombospondin related adhesive protein
showed similar anomalous migration on SDS-
PAGE [36]. Possible microheterogeneity in glycosyl-
ation and the presence of MSA-2 molecules with and
without other post-translational modi¢cations in
parasites may be further reasons for the broad and
sometimes split band of MSA-2 observed in Western
blots of parasite lysates.
The production of antibodies in rabbits in re-
sponse to injection of the plasmids establish the ex-
pression of MSA-2 and the MSA-1 fragment in rab-
bit tissues under the control of the CMV promoter
and intron A enhancer. The promoter of the human
CMV major immediate early gene and the intron A
enhancer from the same gene have proved to be ef-
fective in controlling protein expression in di¡erent
cell types [25,26,37]. However, expression of MSA-2
was also observed in the absence of the intron A
enhancer in these studies. Intradermal inoculation
with a tuberculin applicator was about as e¡ective
as intramuscular injection of plasmid DNA for gen-
erating rabbit antibodies to MSA-2. Plasmid DNA
introduced intradermally may transfect skin Langer-
hans cells which are particularly e¡ective antigen pre-
senting cells. Introduction of mRNA bound to
DOTAP liposomes into rabbit tissues also proved
immunogenic, but the presence of an (A)35 tail in
the mRNA enhanced antibody formation. This is
probably due to the greater stability and/or transla-
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tion e⁄ciency conferred by the poly A tail. Injection
of DNA and capped and polyadenylated mRNA
without cationic liposomes has also been shown to
e⁄ciently transfect muscle tissue [3]. However, injec-
tion of DNA complexed with cationic liposomes may
result in more widespread antigen expression if the
complexes enter the bloodstream [38].
Parameters, such as the amount of nucleic acid
inoculated, number of doses and the interval between
doses, the presence of immunostimulatory DNA se-
quences in the vector [39] and the route of immuni-
sation, in£uence the e⁄cacy of nucleic acid vaccina-
tion and require investigation before clinical trials
are warranted. Safety concerns for eventual human
use, e.g. integration of injected DNA into chromo-
somes, induction of tolerance or autoimmunity and
production of anti-DNA antibodies also need to be
addressed, but the risks appear negligible at present
[40]. The long-term maintenance of antibody levels in
the DNA immunised rabbits is advantageous for nu-
cleic acid vaccination and may be due to the persist-
ence of the plasmid in transfected cells [41]. The per-
sistence of antibodies 15 weeks after inoculation of
BKA mRNA indicates the potential for RNA vacci-
nation. The basis for the comparable stability of
antibody titres after mRNA and DNA mediated
MSA-2 vaccination is not clear. It is possible that,
after either RNA or DNA immunisation, MSA-2 is
only slowly degraded in the transfected cells or that
adequate MSA-2 accumulates on folliclular dendritic
cells in the form of stable immune complexes to stim-
ulate antibody production for several months. The
results also show that, despite poorer relative expres-
sion in Cos cells, the P1/P2 encoding MSA-2 elicited
better antibody titres in rabbits than P3/P4 encoding
a considerably larger MSA-1 protein fragment. The
presence of a greater proportion of repetitive se-
quence in the MSA-2 protein, possible instability of
the MSA-1 protein fragment and di¡erent cellular
localisation of the two proteins may be some of the
factors that in£uence immunogenicity of the two
DNA vaccines.
Considerably greater immunisation e⁄ciency was
reported with biolistic delivery of gold particles
coated with DNA into the epidermis [42]. Antibody
titres s 1033 and cytotoxic T-lymphocyte responses
to in£uenza nucleoprotein were elicited by as little as
16 ng of DNA given in a single dose to mice by
biolistic delivery [42]. Biolistic delivery does not re-
quire cationic lipids such as DOTAP, and the use of
a hand-held gene gun to deliver particle coated DNA
is more appropriate for vaccinating large populations
[42]. VR1012 and VR1020 where problematic se-
quences present in pcDNA3, such as an SV40 origin
and the ampicillin resistance gene, have been deleted
are suitable for human DNA vaccination in this way.
The biolistic delivery of mRNA for immunisation
also merits investigation.
Nucleic acid immunisation is a particularly e¡ec-
tive means of generating cytotoxic T-cell responses
since the protein of interest is synthesised in the cy-
toplasm of the transfected cell and can then be e⁄-
ciently presented by MHC class I molecules on the
surface. Since cytotoxic T-cells are e¡ective against
malaria, parasite infected hepatocytes, the use of nu-
cleic acid vaccination is particularly appropriate for
targeting these stages, and studies in rodent malaria
indicate its usefulness [43]. In addition to liver stage
speci¢c proteins, MSA-1 and MSA-2 synthesised in
infected hepatocytes may provide targets for cyto-
toxic T-cells and Th1-cells that are known to be ef-
fective in eliminating infected hepatocytes [1,43]. This
possibility requires investigation. Th-cells and anti-
bodies are, however, more important for controlling
blood stage malaria infection. Antibodies may act to
block RBC recognition or invasion by merozoites
[6,7], cause complement mediated lysis of merozoites
[34], or promote antibody-dependent, cell-mediated
cytotoxicity against parasites [44^46]. P. falciparum
cultures do not contain leucocytes and therefore only
the ¢rst two mechanisms are potentially operative in
vitro. Inadequate antibody concentration or a⁄nity
may be responsible for the lack of growth inhibition
observed in the experiments. This is an important
consideration since merozoites invade RBC rapidly.
However, we have observed that rabbit antibodies to
a recombinant MSA-2 protein, with Western blotting
and IFA titres of 1036, do not inhibit P. falciparum
growth in vitro and instead promote multiple inva-
sion of RBCs at 2^200 Wg ml31 of total IgG (R.
Ramasamy and S. Yasawardena, unpublished obser-
vations). The ELISA results imply that the antibody
response to MSA-2 in our experiments is directed
predominantly against the allele-speci¢c or non-con-
served regions of the molecule. Repetitive sequences
are prominent in the allele speci¢c regions of MSA-2,
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and also occur in MSA-1. The repeats may help the
parasite escape host immunity by: (1) exhibiting se-
quence polymorphism; (2) preventing the normal
a⁄nity and isotype maturation of the immune re-
sponse; (3) functioning possibly as B-cell superanti-
gens; (4) generating predominantly thymus inde-
pendent antibody responses; and (5) acting as a
sink for binding protective antibodies. The evidence
for such immune evasion mechanisms have been re-
viewed elsewhere [1]. Approximately a quarter of the
MSA-1 sequence at the N-terminus, and including
the repeat region, was used for immunisation in the
present study. The binding to merozoites of mabs
directed against the C-terminal 19 kDa MSA-1 frag-
ment that inhibit proteolytic processing of MSA-1
and also merozoite invasion, can be prevented by
certain other mabs against the 19 kDa fragment [9]
and human polyclonal antibodies against the more
N-terminal region of MSA-1 [47] that do not them-
selves inhibit merozoite invasion or proteolytic proc-
essing. The ability of the parasite to elicit such block-
ing antibodies may constitute another mechanism for
avoiding host immunity. However, other studies in-
dicate a role for the MSA-1 N-terminus in protective
immunity [11,12,19,20,22]. The s 90% inhibition of
parasite growth observed previously with IgG mabs
to MSA-2 at 125 Wg ml31 [5,6] may be the result of
high concentration and a⁄nity and/or speci¢city for
critical epitopes. It is notable in this context that IFA
antibody titres in vaccinees receiving three injections
of recombinant 3D7 MSA-2 in a Phase II clinical
trial, who were subsequently shown not to be pro-
tected, were in the range 1/80 to 1/320 [17]. The de-
velopment of vaccines based on P. falciparum mero-
zoite surface proteins will need to address all these
issues.
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